MARKSANS PHARMA LTD.
NSE : MARKSANSBSE : 524404ISIN
CODE : INE750C01026Industry : Pharmaceuticals & DrugsHouse
: Private
BSE171.955.05 (+3.03 % )
PREV CLOSE (Rs.) 166.90
OPEN PRICE (Rs.) 166.95
BID PRICE (QTY) 171.90 (100 )
OFFER PRICE (QTY) 172.05 (162 )
VOLUME 157248
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE172.10 4.95 (+2.96 % )
PREV CLOSE(Rs.) 167.15
OPEN PRICE (Rs.) 167.50
BID PRICE (QTY) 171.90 (277 )
OFFER PRICE (QTY) 172.10 (162 )
VOLUME 1673061
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 18-Apr-2024 | Marksans Pharma informs about press release | <div style="text-align: justify;">Marksans Pharma has informed that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company located in Vema, Goa, India from 9th April 2024 to 17th April 2024. On conclusion of the inspection, the Company has received 5 inspectional observations in Form 483. There is no data integrity observation. The Company will work closely with the USFDA and is committed to address these observations comprehensively within the stipulated time.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 08-Apr-2024 | Marksans Pharma informs about details of loss of certificate | <div style="text-align: justify;">Marksans Pharma has informed that the Company has received intimation from Registrar and Transfer Agent, Bigshare Services on April 08, 2024 regarding the duplicate share certificates of the Company that have been issued, the details of which are enclosed. Name of Shareholder: Yogesh Anand; Folio Y001026. Pursuant to the SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022 a letter of confirmation will be issued to the securities holder / claimant upon completion of necessary procedures regarding duplicate share certificates.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 03-Apr-2024 | Marksans Pharma informs about loss of share certificate | <div>Marksans Pharma has informed that it received one request from a shareholder for issue of duplicate share certificate in lieu of the lost/ misplaced original Share Certificate. The Registrar and Transfer Agent, Bigshare Services has received the completed documents for issuing duplicate share certificate on April 02, 2024 and pursuant to Regulation 39 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, duplicate share certificate is being issued as per details enclosed. Share holder- Jay Laxmidas Patel, folio- J003199.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 08-Jan-2024 | Marksans Pharma informs about compliance certificate | <div style="text-align: justify;">Marksans Pharma has informed that it enclosed Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for quarter ended December 31, 2023 has been attached.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 02-Jan-2024 | Marksans Pharma informs about issuance of duplicate share certificate | <p style="text-align: justify;">Marksans Pharma has informed that it received one request from a shareholder for issue of duplicate share certificate in lieu of the lost/ misplaced original Share Certificate. Its Registrar and Transfer Agent - Bigshare Services has received the completed documents for issuing duplicate share certificate on January 01, 2024 and pursuant to Regulation 39 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, duplicate share certificate is being issued as per details enclosed. </p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 22-Dec-2023 | Marksans Pharma informs about issuance of duplicate share certificates | <p style="text-align: justify;">Marksans Pharma has informed that it has received intimation from its Registrar and Transfer Agent, Bigshare Services today December 21, 2023 regarding the duplicate share certificates of the Company that have been issued, the details of which are enclosed. Pursuant to the SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022; a letter of confirmation will be issued to the securities holder / claimant upon completion of necessary procedures regarding duplicate share certificates.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 06-Nov-2023 | Marksans Pharma's arm receives Marketing Authorisation for product Cyanocobalamin | <p style="text-align: justify;">Marksans Pharma's wholly owned subsidiary -- Relonchem has received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA. Earlier, the company's wholly owned subsidiary -- Time-Cap Laboratories, Inc. had received Establishment Inspection Report (EIR) from US Food & Drugs Administration (USFDA) for audit conducted in October 2023. No 483's were issued during the Audit. </p><p style="text-align: justify;">Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company's business is distribution of pharmaceutical products.</p> |
| 06-Nov-2023 | Marksans Pharma informs about press release | <div style="text-align: justify;">Marksans Pharma has informed that its wholly owned subsidiary Relonchem has received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 03-Nov-2023 | Marksans Pharma's arm gets EIR from USFDA | <p style="text-align: justify;">Marksans Pharma's wholly owned subsidiary -- Time-Cap Laboratories, Inc. has received Establishment Inspection Report (EIR) from US Food & Drugs Administration (USFDA) for audit conducted in October 2023. No 483's were issued during the Audit.</p><p style="text-align: justify;">Earlier, German health authorities had conducted inspection at Marksans Pharma's newly acquired manufacturing facility located at Verna Industrial Estate, Verna, Goa. The Authorities had not found any critical/major observations but have few recommendations/ minor points which the Company is committed to implement immediately.</p><p style="text-align: justify;">Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company's business is distribution of pharmaceutical products.</p><div style="text-align: justify;"><br></div> |
| 03-Nov-2023 | Marksans Pharma informs about press release | <div style="text-align: justify;">Marksans Pharma has informed about press release titled - ‘Marksans Pharma Limited's wholly owned subsidiary Time-Cap Laboratories, Inc, receives Establishment Inspection Report from US FDA'.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
